CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

NCT05260528 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

248

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Cytarabine and Idarubicin
DRUG: CPX-315

Sponsor

Centre Hospitalier Universitaire de Nice

Collaborators

[object Object]
[object Object]